DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Rexer H. et al.
Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO: A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma.
Urologe A 2017;
56: 802-803
Access:
We do not assume any responsibility for the contents of the web pages of other providers.